Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.
about
Structural Basis for Treating Tumor Necrosis Factor (TNF )-associated Diseases with the Therapeutic Antibody InfliximabGeneration of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytesMethodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies.Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapyEfficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses.Structure based antibody-like peptidomimetics.A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying processMonoclonal antibodies based on hybridoma technology.Liquid formulations for long-term storage of monoclonal IgGs.Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.Molecular and functional analysis of monoclonal antibodies in support of biologics development.Liquid formulations for stabilizing IgMs during physical stress and long-term storage."Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies.Preparation of monoclonal antibody against human KIAA0100 protein and Northern blot analysis of human KIAA0100 gene.Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice.Analysis of the Current Situation of Antitumor Drug Use in China
P2860
Q27676857-1C592E7A-9E2B-482D-A183-60B5B1A8C363Q30352589-BED8A28F-C3A7-4B05-AF78-F15A05A61BFAQ34220190-235BEF5C-8C4B-4D98-97DC-FCDB289FC336Q36982369-88D37DFF-25DB-422B-9567-7AAD53F0C5F1Q37136824-0868EF3F-CC75-434A-833A-E1B4F86570A8Q37148681-C25C1CB3-206D-4B0D-B54A-B3F1669F1919Q37679799-9243FB87-F6DF-4F8A-8065-A60AAC369722Q38162972-3F4C5F81-866F-4642-A587-7F4C221A21ABQ38318567-6DFCC111-39A8-4241-BE34-77BF29410769Q38981429-2E60DD74-6392-4B40-90F6-3A20A8F4A375Q39287960-9EE1139C-BBD9-425C-B1C5-8FC0EFDDDBC9Q39451572-FB923EA2-1811-4292-9A94-84AA65DEE2EDQ44480024-0A9CB187-DE49-4AA2-AD3E-9B230071947EQ47400957-FCDA732A-B78A-4DB0-B63F-432BBA5C8D4EQ49411276-25792A8C-569D-44CA-A4AB-BAC90B1A67D2Q53662159-24B1750C-D30A-4B0C-BE7D-1467E3938EFEQ57552230-B09D7545-F7DF-449B-8845-EF8E7ECD38B4
P2860
Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Monoclonal antibodies - a prov ...... c modality for human diseases.
@en
type
label
Monoclonal antibodies - a prov ...... c modality for human diseases.
@en
prefLabel
Monoclonal antibodies - a prov ...... c modality for human diseases.
@en
P2860
P1433
P1476
Monoclonal antibodies - a prov ...... c modality for human diseases.
@en
P2093
Zhiqiang An
P2860
P2888
P304
P356
10.1007/S13238-010-0052-8
P577
2010-04-01T00:00:00Z